The purpose of this observational study is to collect additional information regarding long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical practice.
Study Type
OBSERVATIONAL
Enrollment
288
Little Rock Allergy and Asthma Clinic
Little Rock, Arizona, United States
Allergy Center at Brookstone
Columbus, Georgia, United States
Rush Presbyterian - St. Lukes Medical Center
To monitor and further explore the overall safey of canakinumab focusing in serious infections
Time frame: At least 5 years
Long-term impact of Ilaris on disease progression (including systemic AA amyloidosis as evidenced by renal function, neurologic and ophthalmologic symptoms, and sensorineural deafness)
Time frame: At least 5 years
Growth and development patterns of children aged 4 to 18 years of age exposed to Ilaris
Time frame: at least 5 years
Identify previously unrecognized serious adverse drug reactions in the treated population
Time frame: at least 5 years
Usage and patterns of dosing of Ilaris in routine clinical practice
Time frame: at least 5 years
Incidence of serious infections
Time frame: at least 5 years
Incidence of malignancies
Time frame: at least 5 years
Incidence of hypersensitivity reactions
Time frame: at least 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Chicago, Illinois, United States
Novartis Investigative site
Bregenz, Austria
Novartis Investigative site
Vienna, Austria
Novartis Investigative site
Dresden, Germany
Novartis Investigative site
Hamburg, Germany
Novartis Investigative site
Heidelberg, Germany
Novartis Investigative site
Herne, Germany
Novartis Investigative site
Kiel, Germany
...and 7 more locations